LMAT Stock Overview
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
LeMaitre Vascular, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$76.00 |
| 52 Week High | US$76.24 |
| 52 Week Low | US$44.27 |
| Beta | 0.88 |
| 1 Month Change | 13.50% |
| 3 Month Change | 23.62% |
| 1 Year Change | 16.62% |
| 3 Year Change | 56.25% |
| 5 Year Change | 169.89% |
| Change since IPO | 1,125.81% |
Recent News & Updates
Recent updates
LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Popularity With Investors Is Clear
May 02
Is Now The Time To Put LeMaitre Vascular (NASDAQ:LMAT) On Your Watchlist?
Apr 04Calculating The Fair Value Of LeMaitre Vascular, Inc. (NASDAQ:LMAT)
Feb 29What Does LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Share Price Indicate?
Jan 19Returns On Capital At LeMaitre Vascular (NASDAQ:LMAT) Paint A Concerning Picture
Oct 27Is It Too Late To Consider Buying LeMaitre Vascular, Inc. (NASDAQ:LMAT)?
Oct 11Does LeMaitre Vascular (NASDAQ:LMAT) Deserve A Spot On Your Watchlist?
Aug 30The Returns On Capital At LeMaitre Vascular (NASDAQ:LMAT) Don't Inspire Confidence
Jul 06Is LeMaitre Vascular, Inc. (NASDAQ:LMAT) Worth US$62.3 Based On Its Intrinsic Value?
May 20Should You Think About Buying LeMaitre Vascular, Inc. (NASDAQ:LMAT) Now?
Mar 12Should You Think About Buying LeMaitre Vascular, Inc. (NASDAQ:LMAT) Now?
Oct 23Calculating The Fair Value Of LeMaitre Vascular, Inc. (NASDAQ:LMAT)
Oct 05LeMaitre Vascular (NASDAQ:LMAT) Could Be Struggling To Allocate Capital
Sep 13LeMaitre Vascular: Reiterate Buy Thesis Following Strong Q2 Numbers
Sep 08LeMaitre Vascular goes ex dividend tomorrow
Aug 23LeMaitre Vascular: 16% Return Objective From Idiosyncratic Risk Premia
Jun 24What Does LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Share Price Indicate?
Jun 15Are Investors Undervaluing LeMaitre Vascular, Inc. (NASDAQ:LMAT) By 40%?
May 06Shareholder Returns
| LMAT | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 13.8% | 1.2% | 2.7% |
| 1Y | 16.6% | -0.05% | 26.0% |
Return vs Industry: LMAT exceeded the US Medical Equipment industry which returned -1.9% over the past year.
Return vs Market: LMAT underperformed the US Market which returned 25% over the past year.
Price Volatility
| LMAT volatility | |
|---|---|
| LMAT Average Weekly Movement | 6.5% |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: LMAT has not had significant price volatility in the past 3 months.
Volatility Over Time: LMAT's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 622 | George LeMaitre | www.lemaitre.com |
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries.
LeMaitre Vascular, Inc. Fundamentals Summary
| LMAT fundamental statistics | |
|---|---|
| Market cap | US$1.68b |
| Earnings (TTM) | US$33.95m |
| Revenue (TTM) | US$199.89m |
50.2x
P/E Ratio8.5x
P/S RatioIs LMAT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LMAT income statement (TTM) | |
|---|---|
| Revenue | US$199.89m |
| Cost of Revenue | US$67.06m |
| Gross Profit | US$132.83m |
| Other Expenses | US$98.88m |
| Earnings | US$33.95m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.51 |
| Gross Margin | 66.45% |
| Net Profit Margin | 16.99% |
| Debt/Equity Ratio | 0% |
How did LMAT perform over the long term?
See historical performance and comparisonDividends
0.8%
Current Dividend Yield38%
Payout RatioDoes LMAT pay a reliable dividends?
See LMAT dividend history and benchmarks| LeMaitre Vascular dividend dates | |
|---|---|
| Ex Dividend Date | May 15 2024 |
| Dividend Pay Date | May 30 2024 |
| Days until Ex dividend | 5 days |
| Days until Dividend pay date | 20 days |
Does LMAT pay a reliable dividends?
See LMAT dividend history and benchmarks